Moderna announced Wednesday positive results from a clinical trial of mRNA-1083, its combination mRNA combination flu/COVID vaccine.
In summary, the data from the Phase 1/2 trial demonstrate that mRNA-1083 generated a strong immune response against all four flu strains, compared to a standard dose influenza vaccine (Fluarix) in adults 50-64 years of age and against an enhanced influenza vaccine (Fluzone HD) in adults 65-79 years of age.
Furthermore, mRNA-1083 also generated a strong immune response compared to the company’s Spikevax COVID vaccine. The company also noted in a press release that mRNA-1083 was safe and tolerable and the rates of adverse side effects were similar to those experienced by people who received the Spikevax vaccine during the study.
Moderna’s trial in adults 50+ will be launching later this year!
“With today’s positive results from our combination vaccine against flu and COVID-19, we continue to expand our Phase 3 pipeline,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Flu and COVID-19 represent a significant seasonal burden for individuals, providers, healthcare systems and economies. Combination vaccines offer an important opportunity to improve consumer and provider experience, increase compliance with public health recommendations, and deliver value for healthcare systems. We are excited to move combination respiratory vaccines into Phase 3 development and look forward to partnering with public health officials to address the significant seasonal threat posed to people by these viruses.”
The ongoing Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT05827926) is a randomized, observer blind study evaluating the safety and immunogenicity of mRNA-1083 compared to a standard dose influenza vaccine, Fluarix, in adults 50-64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65-79 years of age. For both age groups, mRNA-1083 was compared against Spikevax booster.